After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Prime Medicine Inc (PRME) shows that investor sentiment remained same, with the stock’s consolidated last price to $7.76. The Prime Medicine Inc has recorded 1,911 volume in the after hours trading session.
PRME belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $7.76 and fluctuated between $8.64 as its day high and $7.58 as its day low. The current market capitalization of Prime Medicine Inc is $754.82M. A total of 0.76 million shares were traded on the day, compared to an average of 430.76K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, PRME has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 52 SELLs from insiders. Insiders purchased 0 shares during that period but sold 2,980,974.
In the most recent transaction, GV 2019 GP, L.L.C. sold 19,003 shares of PRME for 14.97 per share on Jun 21. After the transaction, the 10% Owner now owns 0 company shares. In a previous transaction on Jun 20, GV 2019 GP, L.L.C. sold 37,405 shares at 15.06 per share. PRME shares that 10% Owner owns now total 0.
Among the insiders who sold shares, GV 2019 GP, L.L.C. disposed of 6,532 shares on Jun 16 at a per-share price of $15.02. This resulted in the 10% Owner holding 0 shares of PRME after the transaction. In another insider transaction, GV 2019 GP, L.L.C. sold 66,659 shares at $14.92 per share on Jun 15. Company shares held by the 10% Owner now total 0.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for PRME in the last 3 months, the mean price target is $21.29 with high estimates of $27.00 and low estimates of $18.00. In terms of 52-week highs and lows, PRME has a high of $21.73 and a low of $5.54.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. PRME’s latest balance sheet shows that the firm has $269.62M in Cash & Short Term Investments as of fiscal 2021. There were $10.41M in debt and $57.98M in liabilities at the time. Its Book Value Per Share was $1.99, while its Total Shareholder’s Equity was $239.56M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PRME is Buy with a score of 4.43.